HRP20040671A2 - Imidazoquinoline derivatives - Google Patents
Imidazoquinoline derivativesInfo
- Publication number
- HRP20040671A2 HRP20040671A2 HR20040671A HRP20040671A HRP20040671A2 HR P20040671 A2 HRP20040671 A2 HR P20040671A2 HR 20040671 A HR20040671 A HR 20040671A HR P20040671 A HRP20040671 A HR P20040671A HR P20040671 A2 HRP20040671 A2 HR P20040671A2
- Authority
- HR
- Croatia
- Prior art keywords
- imidazoquinoline derivatives
- imidazoquinoline
- derivatives
- Prior art date
Links
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0105406A HUP0105406A3 (en) | 2001-12-21 | 2001-12-21 | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
PCT/HU2002/000144 WO2003053969A1 (en) | 2001-12-21 | 2002-12-17 | Imidazoquinoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20040671A2 true HRP20040671A2 (en) | 2005-08-31 |
Family
ID=47711504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20040671A HRP20040671A2 (en) | 2001-12-21 | 2004-07-20 | Imidazoquinoline derivatives |
Country Status (23)
Country | Link |
---|---|
US (1) | US7176213B2 (hu) |
EP (1) | EP1456205A1 (hu) |
JP (1) | JP4530663B2 (hu) |
KR (2) | KR20070034136A (hu) |
CN (1) | CN1307174C (hu) |
AU (1) | AU2002353241B2 (hu) |
BR (1) | BR0215272A (hu) |
CA (1) | CA2470067C (hu) |
EA (1) | EA007226B1 (hu) |
HR (1) | HRP20040671A2 (hu) |
HU (1) | HUP0105406A3 (hu) |
IL (2) | IL162443A0 (hu) |
IS (1) | IS7317A (hu) |
MA (1) | MA27240A1 (hu) |
MX (1) | MXPA04006115A (hu) |
NO (1) | NO329743B1 (hu) |
NZ (1) | NZ534015A (hu) |
PL (1) | PL370761A1 (hu) |
RS (1) | RS56104A (hu) |
TN (1) | TNSN04105A1 (hu) |
UA (1) | UA78745C2 (hu) |
WO (1) | WO2003053969A1 (hu) |
ZA (1) | ZA200404807B (hu) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1430032A2 (en) * | 2001-09-24 | 2004-06-23 | Elan Pharmaceuticals, Inc. | Substituted amides for the treatment of neurological disorders |
HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
HUP0400812A2 (en) * | 2004-04-19 | 2006-02-28 | Sanofi Aventis | Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them |
JP2008531502A (ja) * | 2005-02-22 | 2008-08-14 | ザ レジェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 胃腸の炎症を処置する方法 |
HUP0700395A2 (en) * | 2007-06-07 | 2009-03-02 | Sanofi Aventis | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
US8357132B1 (en) | 2009-10-21 | 2013-01-22 | Lekweuwa Agatha N | Urine capturing assembly |
KR20210007046A (ko) | 2013-02-01 | 2021-01-19 | 웰스태트 테러퓨틱스 코포레이션 | 항염증, 항진균, 항기생충, 및 항암 활성을 갖는 아민 화합물 |
ES2578363B1 (es) | 2015-01-22 | 2017-01-31 | Palobiofarma, S.L. | Moduladores de los receptores A3 de adenosina |
WO2017023905A1 (en) * | 2015-08-03 | 2017-02-09 | Bristol-Myers Squibb Company | Heterocyclic compounds useful as modulators of tnf alpha |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4075343A (en) * | 1976-09-13 | 1978-02-21 | Pfizer Inc. | Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof |
GB1596652A (en) * | 1977-01-20 | 1981-08-26 | Roussel Lab Ltd | Imidazo (1,2-a) quinoline-2-carboxylic acid and derivatives |
SE441449B (sv) | 1979-02-09 | 1985-10-07 | Roussel Uclaf | Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat |
GR76063B (hu) * | 1981-04-03 | 1984-08-03 | Roussel Uclaf | |
HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
-
2001
- 2001-12-21 HU HU0105406A patent/HUP0105406A3/hu unknown
-
2002
- 2002-12-17 EA EA200400847A patent/EA007226B1/ru not_active IP Right Cessation
- 2002-12-17 EP EP02788261A patent/EP1456205A1/en not_active Withdrawn
- 2002-12-17 US US10/499,251 patent/US7176213B2/en not_active Expired - Fee Related
- 2002-12-17 CN CNB02825645XA patent/CN1307174C/zh not_active Expired - Fee Related
- 2002-12-17 CA CA2470067A patent/CA2470067C/en not_active Expired - Fee Related
- 2002-12-17 JP JP2003554685A patent/JP4530663B2/ja not_active Expired - Fee Related
- 2002-12-17 UA UA20040706065A patent/UA78745C2/uk unknown
- 2002-12-17 MX MXPA04006115A patent/MXPA04006115A/es active IP Right Grant
- 2002-12-17 PL PL02370761A patent/PL370761A1/xx not_active Application Discontinuation
- 2002-12-17 WO PCT/HU2002/000144 patent/WO2003053969A1/en active Application Filing
- 2002-12-17 NZ NZ534015A patent/NZ534015A/en not_active IP Right Cessation
- 2002-12-17 KR KR1020077004953A patent/KR20070034136A/ko not_active Application Discontinuation
- 2002-12-17 AU AU2002353241A patent/AU2002353241B2/en not_active Ceased
- 2002-12-17 RS YU56104A patent/RS56104A/sr unknown
- 2002-12-17 IL IL16244302A patent/IL162443A0/xx unknown
- 2002-12-17 BR BR0215272-0A patent/BR0215272A/pt not_active IP Right Cessation
- 2002-12-17 KR KR1020047009788A patent/KR100725298B1/ko not_active IP Right Cessation
-
2004
- 2004-06-07 MA MA27725A patent/MA27240A1/fr unknown
- 2004-06-08 TN TNP2004000105A patent/TNSN04105A1/en unknown
- 2004-06-10 IL IL162443A patent/IL162443A/en not_active IP Right Cessation
- 2004-06-16 IS IS7317A patent/IS7317A/is unknown
- 2004-06-17 ZA ZA200404807A patent/ZA200404807B/xx unknown
- 2004-07-20 HR HR20040671A patent/HRP20040671A2/xx not_active Application Discontinuation
- 2004-07-20 NO NO20043117A patent/NO329743B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1307174C (zh) | 2007-03-28 |
HUP0105406A2 (hu) | 2003-10-28 |
CA2470067C (en) | 2011-02-15 |
ZA200404807B (en) | 2005-08-29 |
JP4530663B2 (ja) | 2010-08-25 |
NO329743B1 (no) | 2010-12-13 |
UA78745C2 (en) | 2007-04-25 |
PL370761A1 (en) | 2005-05-30 |
TNSN04105A1 (en) | 2006-06-01 |
CA2470067A1 (en) | 2003-07-03 |
EP1456205A1 (en) | 2004-09-15 |
IS7317A (is) | 2004-06-16 |
KR20040072670A (ko) | 2004-08-18 |
KR100725298B1 (ko) | 2007-06-07 |
KR20070034136A (ko) | 2007-03-27 |
AU2002353241B2 (en) | 2008-07-10 |
IL162443A (en) | 2010-05-17 |
HUP0105406A3 (en) | 2003-12-29 |
IL162443A0 (en) | 2005-11-20 |
NZ534015A (en) | 2005-04-29 |
MXPA04006115A (es) | 2005-06-08 |
CN1606555A (zh) | 2005-04-13 |
EA200400847A1 (ru) | 2004-12-30 |
WO2003053969A1 (en) | 2003-07-03 |
JP2005516956A (ja) | 2005-06-09 |
US7176213B2 (en) | 2007-02-13 |
MA27240A1 (fr) | 2005-03-01 |
NO20043117L (no) | 2004-07-20 |
US20050070566A1 (en) | 2005-03-31 |
RS56104A (en) | 2006-10-27 |
AU2002353241A1 (en) | 2003-07-09 |
EA007226B1 (ru) | 2006-08-25 |
HUP0105406D0 (en) | 2002-03-28 |
BR0215272A (pt) | 2004-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1068608A1 (en) | 3-Substituted-4-pyrimidone derivatives | |
HK1208446A1 (en) | Derivatives of uk-2a uk-2a | |
ZA200309522B (en) | Substituted cyclohexane-1-4diamine derivatives | |
EG24669A (en) | Antivral azaindole derivatives | |
HK1066218A1 (en) | Qunazoline derivatives as antitumor agents | |
HK1054042A1 (en) | 2-Aminocarbonyl-9h-purine derivatives | |
AU2002352142A1 (en) | Pyrazolopyridine derivatives | |
HUP0402171A3 (en) | Pyrazolopyrimidinone derivatives having pde7-inhibitory activity | |
IL158388A0 (en) | Novel arylheteroalkylamine derivatives | |
HK1068607A1 (en) | Phenylalkyloxy-phenyl derivatives | |
HUP0303449A3 (en) | Substituted benzofuran-2-carboxamides derivatives | |
EP1353546A4 (en) | METHOD AND DEVICE FOR MONITORING PULSATION FOR TREATMENT DEVICE | |
HUP0303186A3 (en) | 4-aminobenzopyran derivatives | |
HUP0401949A3 (en) | 4-imidazolin-2-one derivatives | |
HUP0500026A3 (en) | N-heteroarylnicotinamide derivatives | |
HRP20040671A2 (en) | Imidazoquinoline derivatives | |
HK1052499A1 (zh) | 氨基磺酰基聯苯基衍生物 | |
IL160539A0 (en) | Anti-influenzal agents | |
AU2002350942A8 (en) | Imidazolidineacetic acid derivatives | |
EP1364954A4 (en) | Dicarba closo DODECARBORANDERIVATE | |
HUP0401162A3 (en) | Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives | |
GB0125492D0 (en) | Formulation | |
GB2397817B (en) | Coumarin derivatives | |
HK1048117A1 (zh) | 2-苯基吡喃-4-酮衍生物 | |
GB2396812B (en) | Formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20101109 Year of fee payment: 9 |
|
OBST | Application withdrawn |